World Health Organization site
Untitled
Immunization surveillance, assessment and monitoring Monitoring immunization systems and safety Assessing diseases burden and immunization impact Vaccine preventable diseases Data statistics and graphics Guidelines tools and publications
Country selection form
Last update: 10 August 2009
Next overall update: December 2009
 		Immunization Profile - Guatemala
Development status: Developing GNI / capita (US$):1 2'680 Infant (under 12 months) mortality rate:2§ 29
GDP / capita (US$):1 4'760 Child (under 5 years) mortality rate:2§ 39
Population data in thousands   3
  2008 2007 2006 2005 2004 2000 1990 1980
Total population 13'686 13'354 13'029 12'710 12'397 11'231 8'910 7'016
Live births 453 449 445 440 436 413 350 303
Surviving infants 439 435 430 425 420 396 329 277
Pop. less than 5 years 2'118 2'093 2'066 2'036 2'004 1'863 1'520 1'265
Pop. less than 15 years 5'781 5'685 5'587 5'484 5'378 4'948 4'043 3'184
Female 15-49 years 3'330 3'228 3'131 3'037 2'948 2'627 1'956 1'548
Number of reported cases (Click for full incidence time series from 1980 for Guatemala)
 
Diphtheria 0 0 0 0 0 0 2 9
Japanese encephalitis    -    -    -    -    -    -    -    -
Measles 0 0 0 0 0 0 8'802 2'703
Mumps 627 2    - 1'807 2'164    -    -    -
Pertussis 60 97 48 0 391 146 130 1'513
Polio  * 0 0 0 0 0 0 3 287
Rubella 0 0 11 4 36 276    -    -
Rubella (CRS) 0 0    - 1 2    -    -    -
Tetanus (neonatal) 1 2 2 0 1 7 60 0
Tetanus (total) 2 3 8 6 3 11 41 60
Yellow fever 0    -    - 0 0    -    -    -
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV);
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
Percent of target population vaccinated, by antigen Hovering over an antigen reveals its fuller definition 
  Last coverage survey 4   Official country estimates 5
  (Click for full official coverage time series from 1980 for Guatemala)
  Year Result  
BCG 2001 92        99 97 96 97 98 95 62 36
DTP1 2001 93        99* 96 95 99* 98 94    -    -
DTP3 2001 77        96 93 91 92 92 95 66 43
HepB1 (birth dose)    -    -    -    -    -    -    -    -    -    -
HepB3    -    - 96 93 91 92    -    -    -    -
Hib3    -    - 96 93 91 92    -    -    -    -
JapEnc    -    -    -    -    -    -    -    -    -    -
MCV 2001 75        96 93 95 95 95 86 68 23
MCV2    -    -    -    -    -    -    - 59    -    -
PCV1    -    -    -    -    -    -    -    -    -    -
PCV3    -    -    -    -    -    -    -    -    -    -
Pol3 2001 78        96 93 92 92 93 93 74 43
Rota1    -    -    -    -    -    -    -    -    -    -
Rota_last    -    -    -    -    -    -    -    -    -    -
Rubella1    -    - 96    -    - 93 95    -    -    -
TT2plus 2001 49           -    - 9 92    - 22 27 1
PAB    -    -    -    -    -    -    -    -    -    -
VAD1    -    - 66 40 74 64 52 49    -    -
YFV    -    -    -    -    -    -    -    -    -    -
  WHO-UNICEF coverage estimates.6
  (Click for full WHO-UNICEF coverage estimates time series from 1980 for Guatemala)
 
BCG 99 97 96 97 98 95 62 36
DTP1 95 94 93 93 93 94 86 68
DTP3 85 82 80 81 81 84 66 43
HepB3 85 82 80 81    -    -    -    -
Hib3 85 82 80 81    -    -    -    -
MCV 96 93 95 95 95 86 68 23
PAB 71 71 70 70 70 67 44 1
Pol3 85 82 81 81 83 83 74 43
Number of districts in the country 332  
% of coverage reports received at national level
vs number of reports expected 		100  
Proportion of
districts reporting
DTP3 coverage: 		/
|
|
\
Greater or equal to 90% 80
From 80 to 89% 14
From 50 to 79% 5
Lesser than 50% 1
Proportion of districts not reporting DTP3 coverage 0
Immunization Schedule (2008 or latest available) Hovering over an antigen reveals its fuller definition 
Vaccine Schedule
Vaccine Schedule
BCG        birth;  
DTwP        18 months; 4 years;  
DTwPHibHep        2, 4, 6 months;  
Influenza        >= 50 years;  
 [and HCWs]
MMR        12 months;  
OPV        2, 4, 6, 18 months; 4 years;  
Td        1st contact; +4 weeks; +6 months; +1, +1 year;  
 [or 1st contact; +4 weeks; +6 months; +10, +10 years (if not at risk)]
VitaminA        6,12,18,24,30,36 months  
Immunization indicators  
Indicator Expected answer 2008 2007 2006 2005 2004 2003
Planning and management
Multi-year plan (MYP) for immunization Yes/No/NA No No Yes Yes Yes Yes
What years does the MYP cover? number     2002-2006      
Is MYP costing included? Yes/No/NA     No      
Was there an annual work plan for immunization services? Yes/No/NA Yes Yes Yes Yes Yes Yes
Annual work plan costing included? Yes/No/NA Yes Yes Yes      
Number of districts with microplans that include activities to raise immunization coverage number 332 0       331
% of districts with microplans to raise immunization coverage From 0 to 100% 100 0       100
Year of last inventory of all refrigeration equipment assigned for public immunization services. number 2008 2005 2006      
Are data analyzed at the national level to identify poorly performing districts? Yes/No/NA Yes          
Are outreach session performed at district or lower level? Yes/No/NA Yes          
Is supportive supervision with on-site training performed at district or lower level? Yes/No/NA Yes          
Are meeting held with local leaders at district or lower level? Yes/No/NA Yes          
Is local data analysis performed at district or lower level? Yes/No/NA Yes          
Are other activities performed at district or lower level? text            
 
System performance
Total number of districts in country number 332 332 331 331 331 331
% of coverage report received at national level vs number of reports expected From 0 to 100% 100 100 100 100    
Nº districts had <50% DTP3 coverage number 2 2 2 2 0 0
% districts had <50% DTP3 coverage From 0 to 100% 1 1 1 1 0 0
Nº districts had 50-79% DTP3 number 18 26 36 31 10 13
% districts had 50-79% DTP3 From 0 to 100% 5 8 11 9 3 4
Nº districts had 80-89% DTP3 coverage number 48 56 82 78 52 60
% districts had 80-89% DTP3 coverage From 0 to 100% 14 17 25 24 16 18
Nº districts had >=80% DTP3 coverage number 312 304 293 298 321 318
% districts had >=80% DTP3 coverage From 0 to 100% 94 92 89 90 97 96
Nº districts with 90-94% DTP3 coverage number 33          
% of districts had 90-94% DTP3 coverage From 0 to 100% 10          
Nº districts with >=95% DTP3 coverage number 231          
% of districts with >=95% DTP3 From 0 to 100% 70          
Nº districts had >=90% DTP3 coverage number 264 248 211 220 269 258
% districts had >=90% DTP3 coverage From 0 to 100% 80 75 64 66 81 78
Nº districts not reporting DTP3 number 0 0 0 0 0 0
% districts not reporting DTP3 From 0 to 100% 0 0 0 0 0 0
Nº districts had <50% MCV1 coverage number 1 2 2 1 0 0
% districts had <50% MCV1 coverage From 0 to 100% 0 1 1 0 0 0
Nº districts had 50-79% MCV1 coverage number 16 26 13 23 10 19
% districts had 50-79% MCV1 coverage From 0 to 100% 5 8 4 7 3 6
Nº districts had 80-89% MCV1 coverage number 46 60 43 54 47 77
% districts had 80-89% MCV1 coverage From 0 to 100% 14 18 13 16 14 23
Nº districts had >=80% MCV1 coverage number 315 304 316 307 321 312
% districts had >=80% MCV1 coverage From 0 to 100% 95 92 95 93 97 94
Nº districts with 90-94% MCV1 coverage number 38          
% of districts had 90-94% MCV1 coverage From 0 to 100% 11          
Nº districts with >=95% measles (MCV1) coverage number 231          
% of districts with >=95% MCV1 coverage From 0 to 100% 70          
Nº districts had >=90% MCV1 coverage number 269 244 273 253 274 235
% districts had >=90% MCV1 coverage From 0 to 100% 81 73 82 76 83 71
Nº districts not reporting MCV1 number 0 0 0 0 0 0
% districts not reporting MCV1 From 0 to 100% 0 0 0 0 0 0
Nº districts had <50% TT2+ (pw) coverage number 20   33 66 160 240
% districts had <50% TT2+ (pw) coverage From 0 to 100% 6   10 20 48 73
Nº districts had 50-79% TT2+ (pw) number 93   118 122 104 57
% districts had 50-79% TT2+ (pw) From 0 to 100% 28   36 37 31 17
Nº districts had 80-89% TT2+ (pw) coverage number 38   35 25 26 0
% districts had 80-89% TT2+ (pw) coverage From 0 to 100% 11   11 8   0
Nº districts had >=80% TT2+ (pw) coverage number 219 0 180 143 67 34
% districts had >=80% TT2+ (pw) coverage From 0 to 100% 66 0 54 43 20 10
Nº districts with 90-94% TT2+ coverage number 20          
% of districts had 90-94% TT2+ (pw) coverage From 0 to 100% 6          
Nº districts with >=95% TT2+ (pw) coverage number 161          
% of districts with >=95% TT2+ (pw) From 0 to 100% 48          
Nº districts had >=90% TT2+ (pw) coverage number 181 0 145 118 41 0
% districts had >=90% TT2+ (pw) coverage From 0 to 100% 55 0 44 36 12 0
Nº districts not reporting TT2plus number 0 332 0 0 0 34
% districts not reporting TT2plus From 0 to 100% 0 100 0 0 0 10
Number of districts with >10% DTP drop-out rate number 73     117 71 65
% of districts had >10% drop-out rates From 0 to 100% 22     35 21 20
Drop-out rate between DTP1 and DTP3 coverage From 0 to 100% 4 3 4 12 3 2
% point difference between HepB3 and DTP3 coverage From 0 to 100% 0 0 0 54    
Is there a vaccine wastage monitoring system at service delivery level? Yes/No/NA Yes          
Formula for wastage calculation text Total dosis recibidas menos dosis aplicadas menos el saldo
 
Surveillance
Is there a surveillance system in place for invasive bacterial diseases Yes/No/NA Yes          
Is there a surveillance system in place for rotavirus diarrhoea Yes/No/NA Yes          
 
Vaccine supply
Was there any district with vaccine supply interruption? Yes/No No No     No  
% of districts supplied with sufficient number of AD syringes From 0 to 100% 100 100     100 100
 
Vaccine wastage
BCG vaccines wastage number 59          
National % wastage for DTP From 0 to 100% 9     19 15 25
National % wastage for HepB From 0 to 100% 9         NA
National % wastage for Hib From 0 to 100% 9 4       NA
Pneumococcal conjugate vaccine vaccines wastage number            
Rotavirus vaccines wastage number            
Polio vaccines wastage number 27          
National % wastage for MCV From 0 to 100% 7 2        
Yellow Fever vaccines wastage number            
Tetanus toxoid vaccines wastage number 27          
 
Safety
Activity workplan for immunization injection safety Yes/No/NA No Yes   No Yes Yes
Activity workplan for waste management Yes/No/NA No Yes   No Yes  
Type of injection equipment Ad syringes Yes/No/NA Yes Yes   Yes Yes Yes
No. of districts using AD syringes Injection equipment number 332 332   331 331 331
Type of injection equipment non AD disposables Yes/No/NA Yes No   No Yes No
No. of districts using Non-AD disposables Injection equipment number 332       331  
Type of injection equipment Sterilizables Yes/No/NA No No   No No No
No. of districts using Sterilisables Injection equipment number 0       0  
Are safety boxes distributed with all vaccine deliveries Yes/No/NA Yes Yes   Yes Yes No
Monitoring of Adverse Events Following Immunization (AEFI)? Yes/No/NA Yes Yes   Yes Yes Yes
How many AEFI were reported? number 3     8 24 32
How many AEFI were categorized as "serious" adverse events number 2          
National policy regarding disposal: Incineration Yes/No   Yes   Yes Yes Yes
National policy regarding disposal: Open burning Yes/No   Yes   Yes   Yes
National policy regarding disposal: Burial Yes/No   Yes   Yes Yes Yes
National policy regarding disposal: Other Yes/No Yes         Yes
National policy regarding disposal: No policy Yes/No            
 
Finance
Line item in national budget for vaccines Yes/No/NA No Yes     Yes Yes
What amount of government funds were spent on vaccines number 42297632 8382090 5084933      
Local currency or US$ (government funds on vaccine) text Local currency US $        
Percentage of routine vaccines funded by Government From 0 to 100% 99       100 93
Is the percentage of routine vaccine costs financed by the government an estimate Yes/No Yes          
Line item in national budget for injection supply Yes/No/NA No Yes   Yes Yes Yes
What amount of government funds were spent on routine immunization number 46909661 9002849 7132422      
Local currency or US$ (government funds on immunization) text Local currency          
Immunization spend. Financed using Government funds? From 0 to 100% 100 100     96 100
Is the % of immunization spending financed using Government funds an estimate? Yes/No No          
 
New and under utilized vaccines introduction
Hepatitis B vaccine integrated in routine immunization schedule Yes/Yes [A]/Yes [P]/No Yes Yes Yes Yes No No
Hib vaccine integrated in routine immunization schedule Yes/Yes [P]/No Yes Yes Yes Yes No No
Is Measles 2nd dose vaccine integrated into the routine immunization systems? Yes/No/Yes [P] No No No No No No
Mumps vaccine integrated in routine immunization schedule Yes/No Yes Yes Yes Yes Yes Yes
Pneumococcal vaccine integrated in routine immunization schedule Yes/No/Yes [P]/Yes [R] No No        
Rotavirus vaccine integrated in routine immunization schedule Yes/No/Yes [P]/Yes [R] No No        
Rubella vaccine integrated in routine immunization schedule Yes/No Yes Yes Yes Yes Yes Yes
 
Maternal and neonatal tetanus (NT) elimination
Protection at birth (PAB) against neonatal tetanus From 0 to 100%            
NT eliminated Yes/No Yes Yes Yes Yes Yes Yes
 
Polio eradication
Non-polio AFP rate number 1.5 1.8 2.2 2.2 2.4 2.2
% adequate specimen From 0 to 100% 77 80 77 84 84 91
Confirmed polio number 0 0 0 0 0 0
 
Vitamin A
Vitamin A deficiency status Subclinical (SC); Clinical (C); Possibility of VAD (NDP); VAD unlikely (NDU) SC SC SC SC SC SC
Were Vitamin A supplements distributed with routine services? Yes/No Yes Yes Yes No Yes Yes
Were Vitamin A supplements integrated with campaigns? Yes/No No No No No No Yes
 
Yellow Fever
Member states at risk for Yellow Fever Yes/No No No No No No No
Yellow Fever in schedule Yes/High risk/Partial/No No No No No No No
 
Unless otherwise specified, data provided by Member States through WHO-UNICEF Joint Reporting Form and WHO Regional offices.
1Source: "The 2009 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
2Source: World Health Statistics 2009.
3Source: United Nations, Population Division. The World Population Prospects - the 2008 revision. New York, 2009.
4Source: UNICEF/WHO survey database.
5Source: If no official estimate is available, the administrative coverage is reported. * indicates coverage over 99.5%.
6Source: WHO-UNICEF estimates.

immunization_monitoring_footer
Employment | Other UN Sites | Search | Suggestions | RSS | Privacy
© World Health Organization 2009. All rights reserved